Therefore, the change in anti-VEGF may not protect against the recurrence of a type III hypersensitivity reaction, as illustrated with Patients 1 and 3, who experienced recurrence in cutaneous symptoms after switch to another anti-VEGF. The gene discussed is VEGFA; the disease is type III hypersensitivity disease.